The investigation for the usefulness of carnitine medication in patients with decompensated liver cirrhosis

The investigation for the usefulness of carnitine medication in patients with decompensated liver cirrhosis - The usefulness of carnitine medication in patients with decompensated liver cirrhosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000040441

Enrollment

Registered

2020-06-01

Start date

2020-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

decompensated liver cirrhosis

Interventions

L-carnitine 1500mg/day medication for 12 weeks non administration group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The decompensated liver cirrhosis patients with Child-Pugh score over 7 points

Exclusion criteria

Exclusion criteria: 1)The patient who has already taken carnitine 2)The pregnant woman 3)The breast-feeding women 4)The patient who received other study medicine or the clinical experimental medicine within three months before dosage start of the study

Design outcomes

Primary

Measure	Time frame
the improvement rate of Child-Pugh score after 12weeks from medication start	—

Secondary

Measure	Time frame
the change of grasping power, muscle mass, serum ammonia, neuropsychological test	—

Countries

Japan

Contacts

Public ContactTakuya Adachi

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Gastroenterology and Hepatology

adataku719@yahoo.co.jp086-235-7219

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026